samedan logo
 
 
 
spacer
home > ebr > summer 2019 > the adc jigsaw
PUBLICATIONS
European Biopharmaceutical Review

The ADC Jigsaw

The decades-old war on cancer has yet to be won. While progress has been significant in many indications, mortality rates for some of the most difficult to treat solid tumour types have not improved substantially since the 1970s. For oesophagus and lung cancer, 10-year survival statistics have shown an increase of less than 10%, and pancreatic cancer has shown no improvement at all (1). Furthermore, even in cancers such as melanoma, breast, and uterine where survival rates have improved, more efficacious treatments with fewer debilitating side effects are needed.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Jenny Thirlway leads Iksuda’s ADC programmes, including the preclinical demonstration of Iksuda’s proprietary PermaLink® conjugation chemistry, the exemplification of novel toxin platforms, and the evaluation of partnered antibodies/ alternative scaffolds, focused on the development of a proofof- concept stage ADC portfolio. Jenny has a post-doctoral background in biochemistry and significant experience in the development of biologics, including antibody-based therapeutics and biosimilars.
spacer
Dr Jenny Thirlway
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement